Allergan
Allergan, officially known as Allergan plc, is a prominent global pharmaceutical company headquartered in the United States. Founded in 1948, Allergan has established itself as a leader in the biopharmaceutical industry, focusing on areas such as medical aesthetics, eye care, and neuroscience. The company is renowned for its innovative products, including the widely recognised Botox, which has transformed both cosmetic and therapeutic treatments. With major operational regions spanning North America, Europe, and Asia, Allergan has achieved significant milestones, including its acquisition by AbbVie in 2020, further solidifying its market position. The company’s commitment to research and development has led to a diverse portfolio of unique offerings, making it a key player in enhancing patient outcomes and quality of life.
DitchCarbon Score
How does Allergan's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan's score of 5 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Allergan's reported carbon emissions
Allergan, headquartered in the US, reported its carbon emissions data for various years, with the most recent comprehensive figures available from 2017. In that year, the company emitted approximately 88,190,000 kg CO2e from Scope 1 emissions and about 46,800,000 kg CO2e from Scope 2 emissions, while Scope 3 emissions remained constant at 250,000,000 kg CO2e. Over the years, Allergan has shown a trend of reducing its Scope 1 and 2 emissions, decreasing from about 87,407,000 kg CO2e in 2005 to 88,190,000 kg CO2e in 2017. Notably, the company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a lack of formalised commitments to further reduce its carbon footprint. In summary, while Allergan has made strides in managing its emissions, the absence of defined reduction targets suggests an opportunity for enhanced climate action in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2005 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
